BINDING PROTEINS SPECIFIC FOR RAS NEOANTIGENS AND USES THEREOF
The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
1 .- 93 . (canceled)
94 . A recombinant polynucleotide comprising a nucleic acid sequence encoding a binding protein comprising a T cell receptor (TCR) α-chain and a TCR β-chain, wherein the binding protein is capable of binding to a mutant KRAS peptide and human leukocyte antigen (HLA) complex, wherein the mutant KRAS peptide comprises the amino acid sequence of any one of SEQ ID NOs: 2-5 and the HLA is HLA-A*02;
the α-chain comprises a complementarity determining region (CDR) 1, a CDR2, and a CDR3 comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 220-222, respectively; SEQ ID NOs: 226-228, respectively; SEQ ID NOs: 232-234, respectively; SEQ ID NOs: 238-240, respectively; SEQ ID NOs: 244-246, respectively; SEQ ID NOs: 250-252, respectively; SEQ ID NOs: 256-258, respectively; SEQ ID NOs: 262-264, respectively; SEQ ID NOs: 268-270, respectively; 274-276, respectively; 280-282, respectively; 286-288, respectively;
SEQ ID NOs: 292-294, respectively; SEQ ID NOs: 298-300, respectively; SEQ ID NOs: 304-306, respectively; SEQ ID NOs: 310-312, respectively; SEQ ID NOs: 316-318, respectively; SEQ ID NOs: 322-324, respectively; and SEQ ID NOs: 328, 329, and 340, respectively; and
the β-chain comprises a CDR1, a CDR2, and a CDR3 comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 217-219, respectively; SEQ ID NOs: 223-225, respectively; SEQ ID NOs: 229-231, respectively; SEQ ID NOs: 235-237, respectively;
SEQ ID NOs: 241-243, respectively; SEQ ID NOs: 247-249, respectively; SEQ ID NOs: 253-255, respectively; SEQ ID NOs: 259-261, respectively; SEQ ID NOs: 265-267, respectively; SEQ ID NOs: 271-273, respectively; SEQ ID NOs: 277-279, respectively; SEQ ID NOs: 283-285, respectively; SEQ ID NOs: 289-291, respectively; SEQ ID NOs: 295-297, respectively; SEQ ID NOs: 301-303, respectively; SEQ ID NOs: 307-309, respectively; SEQ ID NOs: 313-315, respectively; SEQ ID NOs: 319-321, respectively; and SEQ ID NOs: 325-327, respectively.
95 . The recombinant polynucleotide of claim 94 , further comprising a heterologous expression control element operatively linked to the binding protein encoding sequence.
96 . The recombinant polynucleotide of claim 94 , wherein the binding protein is a T cell receptor (TCR).
97 . The recombinant polynucleotide of claim 94 , wherein the binding protein is a chimeric antigen receptor (CAR).
98 . The recombinant polynucleotide of claim 94 , further comprising a nucleic acid sequence encoding a self-cleaving peptide, disposed between a nucleic acid sequence encoding the TCR α-chain of the binding protein and a nucleic acid sequence encoding the TCR β-chain of the binding protein.
99 . The recombinant polynucleotide of claim 94 , wherein the nucleic acid sequence is codon-optimized for expression in a host cell.
100 . The recombinant polynucleotide of claim 94 , wherein the polynucleotide is a plasmid.
101 . The recombinant polynucleotide of claim 94 , wherein the polynucleotide is a vector.
102 . The recombinant polynucleotide of claim 101 , wherein the vector is a viral vector.
103 . The recombinant polynucleotide of claim 102 , wherein the viral vector is a γ-retroviral vector or a lentiviral vector.
104 . A host cell comprising a recombinant polynucleotide comprising a nucleic acid sequence encoding a binding protein comprising a T cell receptor (TCR) α-chain and a TCR β-chain, wherein the binding protein is capable of binding to a mutant KRAS peptide and human leukocyte antigen (HLA) complex, wherein the mutant KRAS peptide comprises the amino acid sequence of any one of SEQ ID NOs: 2-5 and the HLA is HLA-A*02;
the α-chain comprises a complementarity determining region (CDR) 1, a CDR2, and a CDR3 comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 220-222, respectively; SEQ ID NOs: 226-228, respectively; SEQ ID NOs: 232-234, respectively; SEQ ID NOs: 238-240, respectively; SEQ ID NOs: 244-246, respectively; SEQ ID NOs: 250-252, respectively; SEQ ID NOs: 256-258, respectively; SEQ ID NOs: 262-264, respectively; SEQ ID NOs: 268-270, respectively; SEQ ID NOs: 274-276, respectively; SEQ ID NOs: 280-282, respectively; SEQ ID NOs: 286-288, respectively; SEQ ID NOs: 292-294, respectively; SEQ ID NOs: 298-300, respectively; SEQ ID NOs: 304-306, respectively; SEQ ID NOs: 310-312, respectively; SEQ ID NOs: 316-318, respectively; SEQ ID NOs: 322-324, respectively; and SEQ ID NOs: 328, 329, and 340, respectively; and
the β-chain comprises a CDR1, a CDR2, and a CDR3 comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 217-219, respectively; SEQ ID NOs: 223-225, respectively; SEQ ID NOs: 229-231, respectively; SEQ ID NOs: 235-237, respectively; SEQ ID NOs: 241-243, respectively; SEQ ID NOs: 247-249, respectively; SEQ ID NOs: 253-255, respectively; SEQ ID NOs: 259-261, respectively; SEQ ID NOs: 265-267, respectively; SEQ ID NOs: 271-273, respectively; SEQ ID NOs: 277-279, respectively; SEQ ID NOs: 283-285, respectively; SEQ ID NOs: 289-291, respectively; SEQ ID NOs: 295-297, respectively; SEQ ID NOs: 301-303, respectively; SEQ ID NOs: 307-309, respectively; SEQ ID NOs: 313-315, respectively; SEQ ID NOs: 319-321, respectively; and SEQ ID NOs: 325-327, respectively.
105 . The host cell of claim 104 , wherein the cell is a T cell.
106 . The host cell of claim 105 , wherein the T cell is a CD8+ T cell, a CD4+ T cell, a CD4−CD8− T cell, a γδ T cell, or a natural killer T cell.
107 . A method of treating a disease or disorder associated with a G12 mutant KRAS, NRAS, or HRAS in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a host cell, wherein the host cell comprises a recombinant polynucleotide comprising a nucleic acid sequence encoding a binding protein comprising a T cell receptor (TCR) α-chain and a TCR β-chain, wherein the binding protein is capable of binding to a mutant KRAS peptide and human leukocyte antigen (HLA) complex, wherein the mutant KRAS peptide comprises the amino acid sequence of any one of SEQ ID NOs: 2-5 and the HLA is HLA-A*02;
the α-chain comprises a complementarity determining region (CDR) 1, a CDR2, and a CDR3 comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 220-222, respectively; SEQ ID NOs: 226-228, respectively; SEQ ID NOs: 232-234, respectively; SEQ ID NOs: 238-240, respectively; SEQ ID NOs: 244-246, respectively; SEQ ID NOs: 250-252, respectively; SEQ ID NOs: 256-258, respectively; SEQ ID NOs: 262-264, respectively; SEQ ID NOs: 268-270, respectively; SEQ ID NOs: 274-276, respectively; SEQ ID NOs: 280-282, respectively; SEQ ID NOs: 286-288, respectively; SEQ ID NOs: 292-294, respectively; SEQ ID NOs: 298-300, respectively; SEQ ID NOs: 304-306, respectively; SEQ ID NOs: 310-312, respectively; SEQ ID NOs: 316-318, respectively; SEQ ID NOs: 322-324, respectively; and SEQ ID NOs: 328, 329, and 340, respectively; and
the β-chain comprises a CDR1, a CDR2, and a CDR3 comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 217-219, respectively; SEQ ID NOs: 223-225, respectively; SEQ ID NOs: 229-231, respectively; SEQ ID NOs: 235-237, respectively; SEQ ID NOs: 241-243, respectively; SEQ ID NOs: 247-249, respectively; SEQ ID NOs: 253-255, respectively; SEQ ID NOs: 259-261, respectively; SEQ ID NOs: 265-267, respectively; SEQ ID NOs: 271-273, respectively; SEQ ID NOs: 277-279, respectively; SEQ ID NOs: 283-285, respectively; SEQ ID NOs: 289-291, respectively; SEQ ID NOs: 295-297, respectively; SEQ ID NOs: 301-303, respectively; SEQ ID NOs: 307-309, respectively; SEQ ID NOs: 313-315, respectively; SEQ ID NOs: 319-321, respectively; and SEQ ID NOs: 325-327, respectively.
108 . The method of claim 107 , wherein the host cell is autologous or allogeneic to the subject.
109 . The method of claim 108 , wherein the host cell is a T cell.
110 . The method of claim 109 , wherein the T cell is a CD8+ T cell, a CD4+ T cell, a CD4−CD8− T cell, a γδ T cell, or a natural killer T cell.
111 . The method of claim 107 , wherein the host cell is configured to produce IFN-γ when in the presence of the peptide:HLA complex.
112 . The method of claim 107 , wherein the host cell is configured to have elevated CD137 expression when in the presence of the mutant KRAS peptide:HLA complex relative to the CD137 expression in a host cell that does not comprise the recombinant polynucleotide.